Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 774-778, 2004.
Artigo
em Chinês
| WPRIM
| ID: wpr-347864
ABSTRACT
To explore therapeutic efficacy of androgens and low dose all-trans retinoic acid (ATRA) for myelodysplastic syndrome (MDS) patients, 55 patients of MDS were observed, including 41 cases of refractory anemia (RA), 11 cases of refractory anemia with excess of blasts (RAEB), 2 cases of refractory anemia with excess of blasts in transformation (RAEB-t) and 1 case of chronic myeloic-monocytic leukemia (CMML). These patients received danazol (600 mg/day) or stanazol (6 mg/day) and ATRA (10 mg/day) for at least 3 months. The results showed that according to MDS international working group response criteria, at the end of three months,complete remission (CR) was seen in 1 patient, partial remission (PR) was found in 2 patients. Hematologic improvement major response (MaR) were seen in 15 patients, minor response (MiR) were seen in 4 patients. The total response rate was 35.8%. In conclusion, danazol or stanazol in combination with low dose ATRA are partialy effective in therapy for patients with low-risk myelodysplastic syndrome.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Tretinoína
/
Síndromes Mielodisplásicas
/
Anemia Refratária
/
Anemia Refratária com Excesso de Blastos
/
Resultado do Tratamento
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Quimioterapia Combinada
/
Doença Hepática Induzida por Substâncias e Drogas
/
Androgênios
Limite:
Adolescente
/
Adulto
/
Idoso
/
Aged80
/
Feminino
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2004
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS